Efficacy, safety, and cancer-related symptoms in patients with hepatocellular carcinoma with alpha-fetoprotein ≥400 ng/ml: A pooled analysis from REACH and REACH-2 studies — Ivan Borbath (2019) | RDL Network
Efficacy, safety, and cancer-related symptoms in patients with hepatocellular carcinoma with alpha-fetoprotein ≥400 ng/ml: A pooled analysis from REACH and REACH-2 studies
Zeitschrift für Gastroenterologie
Article 2019 English
Authors
IB
Ivan Borbath
MK
Masatoshi Kudo
RF
RS Finn
Abstract
1 min read
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death. Advanced stage is associated with symptoms and poor quality-of-life. Ramucirumab (RAM) shows survival benefits in patients with alpha-fetoprotein (AFP) ≥400 ng/ml who failed prior sorafenib treatment. We present efficacy, safety, and cancer-related symptoms in HCC patients with AFp ≥400 ng/ml.
Masatoshi Kudo, Peter R. Galle, Josep M. Llovet, Richard S. Finn, Arndt Vogel, Kenta Motomura, Éric Assenat, Philippe Merle, Giovanni Brandi, Bruno Daniele, Takuji Okusaka, Jiří Tomášek, Christophe Borg, Vincenzo Dadduzio, Manabu Morimoto, Marc Pracht, Min‐Hua Jen, N. Drove Ubreva, Ryan C. Widau, Kenta Shinozaki, Reigetsu Yoshikawa, Andrew X. Zhu
Andrew X. Zhu, Ryan David Nipp, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Jean-Frédéric Blanc, Takuji Okusaka, Ian Chau, David Cella, Allicia C. Girvan, Jonathon Gable, Lee Bowman, Chunxiao Wang, Yanzhi Hsu, Paolo Abada, Masatoshi Kudo
Masatoshi Kudo, Richard S. Finn, Manabu Morimoto, Kun‐Ming Rau, Masafumi Ikeda, Chia‐Jui Yen, Peter R. Galle, Josep M. Llovet, Bruno Daniele, Ho Yeong Lim, David W. McIlwain, Reigetsu Yoshikawa, Kenichi Nakamura, Kun Liang, Chunxiao Wang, Paolo Abada, Ryan C. Widau, Andrew X. Zhu
Masatoshi Kudo, Finn R.S., Manabu Morimoto, Rau K.-M., Masafumi Ikeda, Yen C.-J., Galle P.R., Llovet J.M., Bruno Daniele, Lim H.Y., M. W., Reigetsu Yoshikawa, Kenichi Nakamura, K. Liang, C. Wang, Paolo Abada, Widau R.C., Xiaoli Zhu
Discussion(0)
No comments yet. Be the first to comment.